Community pharmacy briefing for MPs due this week

Community pharmacy briefing for MPs due this week

July 16 2018 Community pharmacy organisations are due to brief MPs at Westminster on Tuesday 17...

GPhC asks for views on publication and disclosure policy update in light of GDPR

GPhC asks for views on publication and disclosure policy update in light of GDPR

July 10 2018 The General Pharmaceutical Council is seeking views on how its publication and...

CMO concludes cannabis products should move out of Schedule 1 classification

CMO concludes cannabis products should move out of Schedule 1 classification

July 9 2018 The Chief Medical Officer has recommended rescheduling cannabis-based products as...

PDA fears GPhC’s new ‘safe and effective pharmacy team’ guidance could be a ‘smokescreen’

PDA fears GPhC’s new ‘safe and effective pharmacy team’ guidance could be a ‘smokescreen’

June 26 2018 The Pharmacists’ Defence Association has raised concerns over aspects in new...

National pharmacy organisations seeking involvement with new NHS Assembly

National pharmacy organisations seeking involvement with new NHS Assembly

June 26 2018 Five national pharmacy organisations have written jointly to NHS England and NHS...

  • Community pharmacy briefing for MPs due this week

    Community pharmacy briefing for MPs due this week

    Monday, 16 July 2018 15:31
  • GPhC asks for views on publication and disclosure policy update in light of GDPR

    GPhC asks for views on publication and disclosure policy update in light of GDPR

    Tuesday, 10 July 2018 09:29
  • CMO concludes cannabis products should move out of Schedule 1 classification

    CMO concludes cannabis products should move out of Schedule 1 classification

    Monday, 09 July 2018 09:18
  • PDA fears GPhC’s new ‘safe and effective pharmacy team’ guidance could be a ‘smokescreen’

    PDA fears GPhC’s new ‘safe and effective pharmacy team’ guidance could be a ‘smokescreen’

    Tuesday, 26 June 2018 15:59
  • National pharmacy organisations seeking involvement with new NHS Assembly

    National pharmacy organisations seeking involvement with new NHS Assembly

    Tuesday, 26 June 2018 15:37

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a lady pharmacist talking to patient cbSeptember 20 2017

The NHS is set to encourage greater uptake of biosimilar medicines in an attempt to cut overall spending on medicines.

Simon Stevens, NHS England Chief Executive, has announced a number of measures to use new technologies and innovations to transform patient care. Among his proposals are to:

  • accelerate and widen the uptake of biosimilars with estimated savings of up to £300m a year by 2021;
  • take up new oral treatments for hepatitis C which could save NHS England more than £50m and save “thousands more lives”;
  • expand the “test-bed programme testing the treatments and care models of tomorrow”.

NHS England says that more biological medicines are due to lose patent exclusivity and more biosimilar medicines are expected to come into the marketplace. “Biosimilars that are already delivering safe, effective treatment for patients and cost savings for the NHS,” include:

  • biosimilar infliximab, used to treat rheumatology conditions and inflammatory bowel disease, which came on the market in March 2015, and is currently being used by 80% of patients;
  • biosimilar etanercept, used to treat rheumatology conditions, which became available in April 2016, and 58% of patients are using it.

“Switching to these two latest biosimilars has already saved the NHS approximately £160 million per annum.”

Earlier this year, biosimilar rituximab, used in cancer and rheumatoid arthritis, became available, and biosimilar adalimumab will become available in 2018, for use in rheumatology conditions and inflammatory bowel disease. “This will offer a biosimilar alternative to the current medicine which accounts for the highest spend in hospitals – more than £300 million in 2015-16,” said NHS England.

“The introduction of lower cost biosimilar medicines has the dual advantage of also driving down the cost of the original drug. For example, the cost per defined daily dose for infliximab has fallen by nearly two-thirds from £16.80 to £6.84.”

Link:
NHS England announcement        

Legal & Policy News

July 16 2018 Community pharmacy’s involvement in managing long term conditions should be better recognised by the Government, parliamentarians have said.
July 11 2018 New Medicines Service data indicates community pharmacists manage 19 out of 20 hypertensive patients without the need to refer a patient back to the GP. Analysis of 131,419 patient...